Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia

Author:

Kim Dae-Young1ORCID,Joo Young-Don2,Lim Sung-Nam2,Kim Sung-Doo1,Lee Jung-Hee1,Lee Je-Hwan1,Kim Dong Hwan (Dennis)3,Kim Kihyun3,Jung Chul Won3,Kim Inho4,Yoon Sung-Soo4,Park Seonyang4,Ahn Jae-Sook5,Yang Deok-Hwan5,Lee Je-Jung5,Lee Ho-Sup6,Kim Yang Soo6,Mun Yeung-Chul7,Kim Hawk8,Park Jae Hoo8,Moon Joon Ho9,Sohn Sang Kyun9,Lee Sang Min10,Lee Won Sik10,Kim Kyoung Ha11,Won Jong-Ho11,Hyun Myung Soo12,Park Jinny13,Lee Jae Hoon13,Shin Ho-Jin14,Chung Joo-Seop14,Lee Hyewon15,Eom Hyeon-Seok15,Lee Gyeong Won16,Cho Young-Uk17,Jang Seongsoo17,Park Chan-Jeoung17,Chi Hyun-Sook17,Lee Kyoo-Hyung1

Affiliation:

1. Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;

2. Department of Internal Medicine, Haeundae Paik Hospital, College of Medicine Inje University, Busan, Korea;

3. Division of Hematology/Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea;

4. Division of Hematology-Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea;

5. Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Korea;

6. Division of Hematology/Oncology, Department of Internal Medicine, Kosin University College of Medicine, Kosin University Gospel Hospital, Busan, Korea;

7. Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea;

8. Division of Hematology and Cellular Therapy, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea;

9. Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea;

10. Department of Hemato-Oncology, Inje University Busan Paik Hospital, Busan, Korea;

11. Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea;

12. Division of Hematology-Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea;

13. Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea;

14. Department of Hematology-Oncology, School of Medicine, Pusan National University Hospital Medical Research Institute, Busan, Korea;

15. Hematologic Oncology Clinic, Center for Specific Organs Center, National Cancer Center, Goyang, Korea;

16. Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea; and

17. Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Abstract

Key Points Nilotinib plus multiagent chemotherapy was feasible and showed a comparable outcome to previous results with imatinib for Ph-pos ALL. The achievement of deep MR with nilotinib at postremission correlated well with the clinical outcomes for Ph-pos ALL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3